Development of Sanofi Pasteur tetravalent dengue vaccine

Development of Sanofi Pasteur tetravalent dengue vaccine

Bibliographic Details
Main Author:	Jean Lang
Format:	Article
Language:	English
Published:	Universidade de São Paulo 2012-10-01
Series:	Revista do Instituto de Medicina Tropical de São Paulo
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652012000700007&lng=en&tlng=en

Similar Items

Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
by: I. Dorigatti, et al.
Published: (2018-09-01)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
by: Hou, Jue, et al.
Published: (2022)

Clinical development of a recombinant live attenuated tetravalent dengue vaccine
by: J. Osorio
Published: (2014-04-01)

Impact of dengue virus genetic diversity on breadth of neutralization by a tetravalent dengue vaccine
by: L. Karwal, et al.
Published: (2020-12-01)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
by: Shibadas Biswal, et al.
Published: (2021-06-01)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
by: Philip K Russell, et al.
Published: (2016-08-01)

Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
by: Ashish Wasudeo Khobragade, et al.
Published: (2021-01-01)

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
by: Claire Y-H Huang, et al.
Published: (2013-01-01)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
by: Maia A Rabaa, et al.
Published: (2017-09-01)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
by: Guy El Helou, et al.
Published: (2020-06-01)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
by: Toshifumi Imagawa, et al.
Published: (2021-09-01)

Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
by: Hui Zhao, et al.
Published: (2014-01-01)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
by: Usha K. Nivarthi, et al.
Published: (2021-02-01)

Long-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate
by: Ran Wang, et al.
Published: (2020-01-01)

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017-04-01)

The Relevance of Tetravalent Influenza Vaccines. World experience
by: A. D. M. E. Osterhaus
Published: (2018-09-01)

A tetravalent dengue nanoparticle stimulates antibody production in mice
by: Silva Elisângela F, et al.
Published: (2012-03-01)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021-03-01)

Prime-boost immunization using adenovirus vector and envelope domain III protein fused with flagellin for tetravalent dengue vaccine development
by: Lin, Guan-Cheng, et al.
Published: (2013)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01)

Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles
by: Yanqi Chan, et al.
Published: (2020-07-01)

Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.
by: Eakachai Prompetchara, et al.
Published: (2014-01-01)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
by: Ajit Kulkarni, et al.
Published: (2017-03-01)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
by: Fiona R Strouts, et al.
Published: (2016-05-01)

Evaluation of a tetravalent DNA vaccine against dengue : integrating biochemical studies on dengue virus envelope protein to a domain-based antigen design
by: Slon Campos, Jose Luis
Published: (2017)

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
by: Sophia Gailhardou, et al.
Published: (2016-07-01)

Inköpsfunktionens interna strategiska betydelse : En fallstudie av Sanofi-Aventis inköpsfunktion
by: Wickberg, Mattias, et al.
Published: (2005)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017-05-01)

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America.
by: Lindsay N Carpp, et al.
Published: (2020-01-01)

The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
by: Hsin-Wei Chen, et al.
Published: (2015-01-01)

Lògiques modals tetravalents
by: Rius Font, Miquel
Published: (1992)

Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients
by: Tobias Moser, et al.
Published: (2021-08-01)

Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease
by: Pei-Lan Shao, et al.
Published: (2009-07-01)

Influenza tetravalent vaccines in national immunization programs for Latin-American countries
by: Macías Hernández, Alejandro E., et al.
Published: (2021)

Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys
by: Masaya Yoshimura, et al.
Published: (2020-07-01)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
by: Stefan W Metz, et al.
Published: (2018-09-01)

Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine
by: Tsung-Han Lin, et al.
Published: (2020-03-01)

A rapid immunization strategy with a live attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates
by: Yuping eAmbuel, et al.
Published: (2014-06-01)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
by: Moffat Malisheni, et al.
Published: (2017-08-01)

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
by: Sanford R Kimmel
Published: (2008-09-01)